CA3228644A1 - Methods and compositions for treating cancer - Google Patents

Methods and compositions for treating cancer Download PDF

Info

Publication number
CA3228644A1
CA3228644A1 CA3228644A CA3228644A CA3228644A1 CA 3228644 A1 CA3228644 A1 CA 3228644A1 CA 3228644 A CA3228644 A CA 3228644A CA 3228644 A CA3228644 A CA 3228644A CA 3228644 A1 CA3228644 A1 CA 3228644A1
Authority
CA
Canada
Prior art keywords
days
compound
administering
weeks
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3228644A
Other languages
English (en)
French (fr)
Inventor
Steven FRUCHTMAN
Matthew PARRIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Traws Pharma Inc
Original Assignee
Onconova Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconova Therapeutics Inc filed Critical Onconova Therapeutics Inc
Publication of CA3228644A1 publication Critical patent/CA3228644A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3228644A 2021-08-12 2022-08-11 Methods and compositions for treating cancer Pending CA3228644A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163232409P 2021-08-12 2021-08-12
US63/232,409 2021-08-12
PCT/US2022/040092 WO2023018891A1 (en) 2021-08-12 2022-08-11 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
CA3228644A1 true CA3228644A1 (en) 2023-02-16

Family

ID=85200519

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3228644A Pending CA3228644A1 (en) 2021-08-12 2022-08-11 Methods and compositions for treating cancer

Country Status (11)

Country Link
US (1) US20240299326A1 (https=)
EP (1) EP4384498A1 (https=)
JP (1) JP2024531238A (https=)
CN (1) CN118076583A (https=)
AU (1) AU2022326485A1 (https=)
CA (1) CA3228644A1 (https=)
CO (1) CO2024002786A2 (https=)
GB (1) GB2628229A (https=)
IL (1) IL310759A (https=)
MX (1) MX2024001935A (https=)
WO (1) WO2023018891A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5156389B2 (ja) * 2005-01-05 2013-03-06 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 薬剤耐性増殖性疾患の治療剤
WO2014089483A1 (en) * 2012-12-07 2014-06-12 Onconova Therapeutics, Inc. Methods and compositions for treatment of cancer
JP2018530590A (ja) * 2015-10-14 2018-10-18 タリックス ファーマシューティカルズ リミテッド 表皮水疱症の処置のための方法及び組成物
CA3076610A1 (en) * 2017-09-22 2019-03-28 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa

Also Published As

Publication number Publication date
WO2023018891A1 (en) 2023-02-16
US20240299326A1 (en) 2024-09-12
GB2628229A (en) 2024-09-18
AU2022326485A1 (en) 2024-02-29
MX2024001935A (es) 2024-03-21
CO2024002786A2 (es) 2024-03-18
GB202402730D0 (en) 2024-04-10
CN118076583A (zh) 2024-05-24
WO2023018891A8 (en) 2023-09-21
IL310759A (en) 2024-04-01
JP2024531238A (ja) 2024-08-29
EP4384498A1 (en) 2024-06-19

Similar Documents

Publication Publication Date Title
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
JP7602272B2 (ja) Ｋｒａｓ関連がんを治療する方法
US20240261288A1 (en) Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
JP7025781B2 (ja) ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法
US20230372346A1 (en) Treatment regimens for exon-20 insertion mutant egfr cancers
JP6240658B2 (ja) 抗がん活性を有する６−オキソ−１，６−ジヒドロ−ピリダジン誘導体と他の抗腫瘍化合物との組み合わせ
WO2024078592A1 (zh) 靶向成纤维细胞活化蛋白的药物及其应用
TW202539662A (zh) 抗腫瘤組合物
US20240299326A1 (en) Methods and compositions for treating cancer
CN115484944B (zh) 使用ccr9抑制剂和抗il-23阻断抗体治疗炎症性肠病的组合物和方法
MD4879C1 (ro) Utilizare a derivatului bisamidic al acidului malonic pentru tratarea bolilor alergice şi altor boli umane şi animaliere
EP3967309B1 (en) Quinoline derivative and antibody toripalimab soft tissue sarcoma combination therapy
US20240366610A1 (en) Methods and compositions for treating cancer
US20240374600A1 (en) Methods and compositions for treating cancer
WO2023230286A2 (en) Methods and compositions for treating cancer
JP2026510002A (ja) Ｅｔｂｒ活性化に関連する癌を処置するための方法
WO2023091724A1 (en) Methods and compositions for treating cancer
CN113631179A (zh) 用于治疗特发性肺纤维化的方法
US20240269099A1 (en) Methods and compositions for treating cancer
WO2026057047A1 (en) Methods of treating glioma
WO2024186641A1 (en) Methods and compositions for treating cancer
JP2026501619A (ja) 薬学的活性化合物、組成物、およびペンドリン調節方法
WO2025247187A1 (zh) 抗trop2抗体药物偶联物和抗pd-l1/cd47双特异抗体联合治疗肿瘤的用途
WO2023230220A2 (en) Methods and compositions for treating cancer
JP2025533120A (ja) イミダゾリジニルバニリン酸エーテル誘導体の線維化を伴う疾患の治療における使用

Legal Events

Date Code Title Description
R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20240815

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240815

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240816

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241025

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250206

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260205